Previous observations were made that the slice variant of SSTR5, namely sst5TMD4, is highly expressed at the level of protein and mRNA in prostate cancer and can govern some pathophysiological roles as a biomarker and/or therapeutic intervention in patients with worse prognosis [249]. Here, SSTR5 is linked to prostate carcinoma.